Literature DB >> 8208394

Medical treatment of Rasmussen's syndrome (chronic encephalitis and epilepsy): effect of high-dose steroids or immunoglobulins in 19 patients.

Y M Hart1, M Cortez, F Andermann, P Hwang, D R Fish, O Dulac, K Silver, N Fejerman, H Cross, A Sherwin.   

Abstract

We treated 19 patients with Rasmussen's syndrome (chronic encephalitis and epilepsy)--a rare progressive disorder of unknown etiology causing focal epilepsy, hemiparesis, and intellectual deterioration--with intravenous immunoglobulins, high-dose steroids, or both, to control seizures and improve the end point of the disease. Ten of 17 patients receiving steroids, and eight of nine patients receiving immunoglobulins, had some reduction of seizure frequency in the short term. Improvement in hemiparesis was slight. The effect of these drugs in ameliorating the end point of the disease in the long term remains unknown, and further multicenter studies with standardized protocols are warranted.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8208394     DOI: 10.1212/wnl.44.6.1030

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  26 in total

1.  Utility of Tc 99m HMPAO SPECT in the early diagnosis of Rasmussen's syndrome.

Authors:  F Paladin; G Capovilla; A Bonazza; R Mameli
Journal:  Ital J Neurol Sci       Date:  1998-08

Review 2.  Future prospects for the drug treatment of epilepsy.

Authors:  A Nicolson; J P Leach
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 3.  [Use of i.v. immunoglobulins in neurology. Evidence-based consensus].

Authors:  M Stangel; R Gold
Journal:  Nervenarzt       Date:  2004-08       Impact factor: 1.214

4.  Rasmussen encephalitis with ipsilateral brain stem involvement in an adult patient.

Authors:  C M Quesada; H Urbach; C E Elger; C G Bien
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-02       Impact factor: 10.154

5.  Humanized mouse model of Rasmussen's encephalitis supports the immune-mediated hypothesis.

Authors:  Hania Kebir; Lionel Carmant; François Fontaine; Kathie Béland; Ciprian M Bosoi; Nathalie T Sanon; Jorge I Alvarez; Sébastien Desgent; Camille L Pittet; David Hébert; Marie-Josée Langlois; Rose-Marie Rébillard; Dang K Nguyen; Cécile Cieuta-Walti; Gregory L Holmes; Howard P Goodkin; John R Mytinger; Mary B Connolly; Alexandre Prat; Elie Haddad
Journal:  J Clin Invest       Date:  2018-04-09       Impact factor: 14.808

6.  In Rasmussen encephalitis, hemichannels associated with microglial activation are linked to cortical pyramidal neuron coupling: a possible mechanism for cellular hyperexcitability.

Authors:  Carlos Cepeda; Julia W Chang; Geoffrey C Owens; My N Huynh; Jane Y Chen; Conny Tran; Harry V Vinters; Michael S Levine; Gary W Mathern
Journal:  CNS Neurosci Ther       Date:  2014-12-01       Impact factor: 5.243

Review 7.  Intravenous immunoglobulin in neurological disease: a specialist review.

Authors:  C M Wiles; P Brown; H Chapel; R Guerrini; R A C Hughes; T D Martin; P McCrone; J Newsom-Davis; J Palace; J H Rees; M R Rose; N Scolding; A D B Webster
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

Review 8.  Rasmussen encephalitis with dual pathology in a patient without seizures: case report and literature review.

Authors:  Vijay M Ravindra; Marcus D Mazur; Carrie A Mohila; Matthew T Sweney; Aimee Hersh; Robert J Bollo
Journal:  Childs Nerv Syst       Date:  2015-06-02       Impact factor: 1.475

Review 9.  [Recent insights into Rasmussen encephalitis].

Authors:  C G Bien; C E Elger
Journal:  Nervenarzt       Date:  2005-12       Impact factor: 1.214

Review 10.  Clinical applications of intravenous immunoglobulins in neurology.

Authors:  R A C Hughes; M C Dalakas; D R Cornblath; N Latov; M E Weksler; N Relkin
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.